| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
(2-pyridyldithio)-PEG1-hydrazine does not have a direct pharmacological target, as it is a linker molecule used in the synthesis of ADCs. Its function is to connect an antibody to a cytotoxic payload in ADC constructs. The pyridyl disulfide group enables thiol-reactive conjugation, while the hydrazine group allows for hydrazone chemistry, which is pH-sensitive and enables payload release in the acidic environment of lysosomes.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1].
(2-pyridyldithio)-PEG1-hydrazine does not possess intrinsic biological activity as it is a linker molecule rather than a pharmacologically active compound. Its in vitro utility lies in its use as a chemical building block for the synthesis of ADCs. The compound's pyridyl disulfide group allows for conjugation to thiol groups, while the hydrazine group enables pH-sensitive hydrazone bond formation. These properties make it useful for developing ADCs with controlled payload release. |
| ln Vivo |
In vivo activity is not applicable to (2-pyridyldithio)-PEG1-hydrazine itself, as it is a linker molecule used in the synthesis of ADCs rather than a pharmacologically active compound. The in vivo activity would be associated with the final ADC molecules that incorporate this linker, not with the linker itself. The compound is used exclusively as a chemical building block in research settings to construct ADC molecules.
|
| Enzyme Assay |
In vitro enzyme/receptor binding experiments are not applicable to (2-pyridyldithio)-PEG1-hydrazine, as it is a linker molecule rather than a biologically active compound. The compound is used as a chemical building block in bioconjugation reactions. Its characterization involves chemical analysis methods such as NMR spectroscopy, HPLC, and mass spectrometry to confirm its structure and purity. Researchers use these analytical techniques to verify the identity and quality of the compound before using it in ADC synthesis.
|
| Cell Assay |
In vitro cellular experiments are not performed with (2-pyridyldithio)-PEG1-hydrazine itself, as it is a linker molecule used in bioconjugation rather than a biologically active compound. The compound is used exclusively as a building block for the synthesis of ADCs. Researchers handling (2-pyridyldithio)-PEG1-hydrazine follow standard chemical synthesis protocols, including the use of appropriate personal protective equipment and working in a fume hood.
|
| Animal Protocol |
In vivo animal experiments are not applicable to (2-pyridyldithio)-PEG1-hydrazine itself, as it is a linker molecule used in the synthesis of ADCs rather than a pharmacologically active compound. The compound is not administered to animals, and its biological effects have not been studied in vivo. Any animal studies would be conducted with the final ADC molecules that are synthesized using this linker, not with the linker itself.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to (2-pyridyldithio)-PEG1-hydrazine itself, as it is a linker molecule used in bioconjugation rather than a pharmacologically active drug candidate. The compound is not intended for administration to animals or humans, and its absorption, distribution, metabolism, and excretion have not been studied. The compound is used exclusively as a building block for the synthesis of ADCs.
|
| Toxicity/Toxicokinetics |
Toxicological data for (2-pyridyldithio)-PEG1-hydrazine are limited, as the compound is a chemical linker rather than a drug candidate. Standard safety precautions for handling organic chemicals apply, including the use of personal protective equipment and working in a well-ventilated area. The compound is not intended for human consumption, and its toxicity profile has not been extensively characterized.
|
| References | |
| Additional Infomation |
(2-pyridyldithio)-PEG1-hydrazine is a research chemical that has not entered clinical trials or received regulatory approval for therapeutic use. It is a cleavable ADC linker used in the synthesis of antibody-drug conjugates. The compound's pyridyl disulfide and hydrazine groups enable thiol-reactive conjugation and pH-sensitive hydrazone chemistry, making it valuable for developing ADCs with controlled payload release. It is also known as 2-(pyridin-2-yldisulfanyl)ethan-1-ol.
|
| Molecular Formula |
C₇H₉NOS₂
|
|---|---|
| Molecular Weight |
187.28
|
| Exact Mass |
187.012
|
| CAS # |
111625-28-6
|
| PubChem CID |
3653053
|
| Appearance |
Colorless to light yellow Solid-Liquid Mixture
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
323.3±38.0 °C at 760 mmHg
|
| Flash Point |
149.3±26.8 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.646
|
| LogP |
2.08
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
11
|
| Complexity |
102
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])C([H])([H])O[H])SC1=C([H])C([H])=C([H])C([H])=N1
|
| InChi Key |
PORTXTUJPQINJC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H9NOS2/c9-5-6-10-11-7-3-1-2-4-8-7/h1-4,9H,5-6H2
|
| Chemical Name |
2-(pyridin-2-yldisulfanyl)ethanol
|
| Synonyms |
(2pyridyldithio)PEG1hydrazine; (2 pyridyldithio) PEG1 hydrazine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3396 mL | 26.6980 mL | 53.3960 mL | |
| 5 mM | 1.0679 mL | 5.3396 mL | 10.6792 mL | |
| 10 mM | 0.5340 mL | 2.6698 mL | 5.3396 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
